Biotech entity
Every one of those 1 sits in a single category, clinical-trial. Of the tracked stories, 1 of 1 also mention Acumen Pharmaceuticals, the most common co-covered peer. Their average consequence score of 7 runs above the beat's 6 for that window.
Last mentioned: Mar 19, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Every one of those 1 sits in a single category, clinical-trial. Of the tracked stories, 1 of 1 also mention Acumen Pharmaceuticals, the most common co-covered peer. Their average consequence score of 7 runs above the beat's 6 for that window. Each story carries 2 original sources on average, compared with 2.6 for the broader beat in this window. We currently track 1 Biotech story that mention JCR Pharmaceuticals, all published on March 19, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 23 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering JCR Pharmaceuticals. Shared-story counts are live from our verified record — not editorial picks.
Acumen Pharmaceuticals is advancing its lead antibody, sabirnetug, through Phase II clinical trials while leveraging a strategic partnership with JCR Pharmaceuticals for enhanced brain delivery. The company has identified 2026 as a critical catalyst year for data readouts that could validate its unique approach to targeting toxic amyloid-beta oligomers.
JCR Pharmaceuticals is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
